Monday, September 14, 2026

IBS Team Uses AI to Discover New Green Hydrogen Catalyst That Outperforms Existing Materials

IBS has developed a technology integrating experimental data of different catalysts into a single AI model to discover new catalysts.

GENESIS OF DOOM: 12-Year-Old Ju Ae Joins Kim Jong Un In Launching “Strategic Deterrence” Firepower

North Korea tested an upgraded large-caliber rocket launcher under Kim Jong Un's supervision, emphasizing strategic deterrence and local development.

MIDLIFE CRISIS RESOLVED: Kim Jong Un Sent Flowers—Two Failed Leaders Huddle For A Communist Bromance

Kim Jong Un inspected local factories to assess progress on regional developments and emphasized the need for skilled labor in production.

Tag: solid tumors

Curocell’s RIMQARTO®: The First CAR-T Therapy in Korea, with Plans for Global Release

Curocell aims to lead in CAR-T therapies with RIMQARTO's approval, focusing on solid tumors and global expansion strategies.

SillaJen’s Breakthrough Cancer BAL0891 Drug Set for ASCO 2026 Reveal

SillaJen's anticancer drug BAL0891 will be presented at the ASCO Annual Meeting, currently in Phase 1 trials for solid tumors and AML.

Samsung Bioepis Launches SBE303: The First ADC Drug Candidate Targeting Nectin-4 in Cancer Trials

Samsung Bioepis has begun Phase 1 trials for its ADC candidate SBE303, targeting solid tumors, set to continue until July 2030.

GC Cell’s CAR-NK: Revolutionizing Solid Tumor Treatment with New Patent

GC Cell has patented an immunotherapy targeting solid tumors using its CAR-NK platform, aiming for safer, cost-effective treatments.

ABL209 Receives FDA Approval: What This Dual Antibody ADC Means for Cancer Treatment

ABL Bio receives FDA approval for ABL209, a bispecific antibody-drug conjugate, advancing ADC development for solid tumors.

New Drug Candidate Shows Promise Against Solid Tumors by Eliminating M2 Macrophages

Researchers have developed a peptide drug that targets M2 macrophages, enhancing solid tumor immunotherapy effectiveness.

Top News

- Our Sponsors Ad -

Follow us